HUP0300974A3 - N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases, pharmaceutical compositions containing them and their use - Google Patents
N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases, pharmaceutical compositions containing them and their useInfo
- Publication number
- HUP0300974A3 HUP0300974A3 HU0300974A HUP0300974A HUP0300974A3 HU P0300974 A3 HUP0300974 A3 HU P0300974A3 HU 0300974 A HU0300974 A HU 0300974A HU P0300974 A HUP0300974 A HU P0300974A HU P0300974 A3 HUP0300974 A3 HU P0300974A3
- Authority
- HU
- Hungary
- Prior art keywords
- oxazolyl
- thiazolyl
- thio
- alkyl
- methyl
- Prior art date
Links
- 108091007914 CDKs Proteins 0.000 title 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 title 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/464,511 US6262096B1 (en) | 1997-11-12 | 1999-12-15 | Aminothiazole inhibitors of cyclin dependent kinases |
US09/616,629 US6214852B1 (en) | 1998-10-21 | 2000-07-26 | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
PCT/US2000/033113 WO2001044241A1 (en) | 1999-12-15 | 2000-12-07 | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0300974A2 HUP0300974A2 (hu) | 2003-08-28 |
HUP0300974A3 true HUP0300974A3 (en) | 2009-03-30 |
Family
ID=27041009
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0300974A HUP0300974A3 (en) | 1999-12-15 | 2000-12-07 | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases, pharmaceutical compositions containing them and their use |
Country Status (22)
Country | Link |
---|---|
US (1) | US6214852B1 (hu) |
EP (1) | EP1240165B1 (hu) |
JP (1) | JP2003525872A (hu) |
KR (1) | KR20020067547A (hu) |
CN (1) | CN1433415A (hu) |
AT (1) | ATE294800T1 (hu) |
AU (1) | AU774381B2 (hu) |
CA (1) | CA2394544A1 (hu) |
CO (1) | CO5251464A1 (hu) |
CZ (1) | CZ20022013A3 (hu) |
DE (1) | DE60019964T2 (hu) |
DK (1) | DK1240165T3 (hu) |
EE (1) | EE200200306A (hu) |
ES (1) | ES2241678T3 (hu) |
HU (1) | HUP0300974A3 (hu) |
PE (1) | PE20010932A1 (hu) |
PL (1) | PL364884A1 (hu) |
PT (1) | PT1240165E (hu) |
SI (1) | SI20975B (hu) |
TW (1) | TWI265930B (hu) |
UY (1) | UY26480A1 (hu) |
WO (1) | WO2001044241A1 (hu) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6262096B1 (en) | 1997-11-12 | 2001-07-17 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
US6414156B2 (en) | 1998-10-21 | 2002-07-02 | Bristol-Myers Squibb Company | Process for preparing azacycloalkanoylaminothiazoles |
US6392053B2 (en) * | 1999-12-15 | 2002-05-21 | Bristol-Myers Squibb Company | Process for preparing arylacetylaminothiazoles |
US6515004B1 (en) | 1999-12-15 | 2003-02-04 | Bristol-Myers Squibb Company | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
US6534531B2 (en) * | 2000-04-27 | 2003-03-18 | Bristol-Myers Squibb Company | Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy |
NZ530524A (en) | 2001-07-19 | 2006-12-22 | Pharmacia Italia S | Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents |
EP1724270A3 (en) * | 2001-07-19 | 2007-01-03 | Pfizer Italia S.r.l. | Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents |
ES2183734B1 (es) * | 2001-08-02 | 2004-06-16 | Consejo Sup. Investigaciones Cientificas | Derivados de 4-4'-bipiridil-2-2'-bisoxazoles y 4-4'-bipiridil-2-2'-bistiazoles como agentes antineoplasicos. |
BR0211626A (pt) * | 2001-08-03 | 2004-08-24 | Novo Nordisk As | Composto, uso do mesmo, composição farmacêutica, e, método para o tratamento de doenças, distúrbios, sìndromes e condições |
CA2455753A1 (en) * | 2001-08-03 | 2003-02-13 | Novo Nordisk A/S | Novel 2,4-diaminothiazole derivatives |
TW200401638A (en) * | 2002-06-20 | 2004-02-01 | Bristol Myers Squibb Co | Heterocyclic inhibitors of kinases |
DE10300124A1 (de) * | 2003-01-07 | 2004-07-15 | Bayer Ag | Verfahren zur Herstellung von Arylalkinen |
AU2004262369A1 (en) * | 2003-07-29 | 2005-02-10 | Bristol-Myers Squibb Company | Biomarkers of cyclin-dependent kinase modulation |
US7888504B2 (en) * | 2006-07-06 | 2011-02-15 | Bristol-Myers Squibb Company | Glucokinase activators and methods of using same |
WO2008049856A2 (en) * | 2006-10-25 | 2008-05-02 | Ingenium Pharmaceuticals Gmbh | Methods of treating pain using cdk inhibitors |
EP2937345B1 (en) | 2009-12-29 | 2018-03-21 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
SI2760860T1 (sl) * | 2011-09-28 | 2017-04-26 | Euro-Celtique S.A. | Derivati dušikove gorčice |
EP3569598A1 (en) | 2011-11-17 | 2019-11-20 | Dana Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
AR092790A1 (es) | 2012-02-01 | 2015-05-06 | Euro Celtique Sa | Derivados bencimidazolicos del acido hidroxamico |
US10112927B2 (en) | 2012-10-18 | 2018-10-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
US9758522B2 (en) | 2012-10-19 | 2017-09-12 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
WO2015058140A1 (en) | 2013-10-18 | 2015-04-23 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) |
WO2015058126A1 (en) | 2013-10-18 | 2015-04-23 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
EP3236959A4 (en) | 2014-12-23 | 2018-04-25 | Dana Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
WO2016160617A2 (en) | 2015-03-27 | 2016-10-06 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
US10702527B2 (en) | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
WO2017044858A2 (en) | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
CA3040155C (en) | 2016-10-11 | 2024-01-16 | Euro-Celtique S.A. | Compound for use in the treatment of hodgkin lymphoma |
GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1088049A (en) | 1975-06-03 | 1980-10-21 | Takashi Masugi | 3-substituted-7-substituted alkanamido-3-cephem-4- carboxylic acid compounds and processes for preparation thereof |
CA1201431A (en) | 1981-12-17 | 1986-03-04 | Daiei Tunemoto | .beta.-LACTAM COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND INTERMEDIATE PRODUCTS FOR THE PREPARATION THEREOF |
TW205041B (hu) | 1989-08-07 | 1993-05-01 | Fujisawa Pharmaceutical Co | |
US5491157A (en) | 1993-05-10 | 1996-02-13 | Eastman Kodak Company | Method and composition for the prevention, control and amelioration of soilborne fungi and disease caused thereby |
IL112721A0 (en) | 1994-03-10 | 1995-05-26 | Zeneca Ltd | Azole derivatives |
JPH10510258A (ja) | 1994-12-09 | 1998-10-06 | 藤沢薬品工業株式会社 | セフェム化合物およびその医薬用途 |
IL117620A0 (en) | 1995-03-27 | 1996-07-23 | Fujisawa Pharmaceutical Co | Heterocyclic compounds processes for the preparation thereof and pharmaceutical compositions containing the same |
AUPN801196A0 (en) | 1996-02-12 | 1996-03-07 | Fujisawa Pharmaceutical Co., Ltd. | New cephem compounds and pharmaceutical use thereof |
ES2256968T3 (es) | 1997-10-27 | 2006-07-16 | Agouron Pharmaceuticals, Inc. | Derivados de 4-aminotiazol, su preparacion y su uso como inhibidores de quinasas dependientes de ciclina. |
US6040321A (en) | 1997-11-12 | 2000-03-21 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
GB9823871D0 (en) | 1998-10-30 | 1998-12-23 | Pharmacia & Upjohn Spa | 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents |
-
2000
- 2000-07-26 US US09/616,629 patent/US6214852B1/en not_active Expired - Lifetime
- 2000-12-07 ES ES00982481T patent/ES2241678T3/es not_active Expired - Lifetime
- 2000-12-07 KR KR1020027007617A patent/KR20020067547A/ko not_active Application Discontinuation
- 2000-12-07 PT PT00982481T patent/PT1240165E/pt unknown
- 2000-12-07 AU AU19506/01A patent/AU774381B2/en not_active Ceased
- 2000-12-07 JP JP2001544731A patent/JP2003525872A/ja active Pending
- 2000-12-07 PL PL00364884A patent/PL364884A1/xx not_active Application Discontinuation
- 2000-12-07 DK DK00982481T patent/DK1240165T3/da active
- 2000-12-07 EP EP00982481A patent/EP1240165B1/en not_active Expired - Lifetime
- 2000-12-07 CA CA002394544A patent/CA2394544A1/en not_active Abandoned
- 2000-12-07 AT AT00982481T patent/ATE294800T1/de active
- 2000-12-07 SI SI200020060A patent/SI20975B/sl not_active IP Right Cessation
- 2000-12-07 HU HU0300974A patent/HUP0300974A3/hu unknown
- 2000-12-07 DE DE60019964T patent/DE60019964T2/de not_active Expired - Lifetime
- 2000-12-07 CN CN00818899A patent/CN1433415A/zh active Pending
- 2000-12-07 EE EEP200200306A patent/EE200200306A/xx unknown
- 2000-12-07 CZ CZ20022013A patent/CZ20022013A3/cs unknown
- 2000-12-07 WO PCT/US2000/033113 patent/WO2001044241A1/en active Search and Examination
- 2000-12-11 TW TW089126395A patent/TWI265930B/zh not_active IP Right Cessation
- 2000-12-14 UY UY26480A patent/UY26480A1/es not_active Application Discontinuation
- 2000-12-14 CO CO00095239A patent/CO5251464A1/es not_active Application Discontinuation
- 2000-12-15 PE PE2000001348A patent/PE20010932A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CO5251464A1 (es) | 2003-02-28 |
EE200200306A (et) | 2003-06-16 |
PL364884A1 (en) | 2004-12-27 |
PE20010932A1 (es) | 2001-11-18 |
CN1433415A (zh) | 2003-07-30 |
DK1240165T3 (da) | 2005-08-08 |
US6214852B1 (en) | 2001-04-10 |
SI20975B (sl) | 2006-04-30 |
ATE294800T1 (de) | 2005-05-15 |
SI20975A (sl) | 2003-02-28 |
DE60019964T2 (de) | 2006-04-27 |
HUP0300974A2 (hu) | 2003-08-28 |
EP1240165B1 (en) | 2005-05-04 |
UY26480A1 (es) | 2001-07-31 |
CZ20022013A3 (cs) | 2003-03-12 |
KR20020067547A (ko) | 2002-08-22 |
PT1240165E (pt) | 2005-09-30 |
AU1950601A (en) | 2001-06-25 |
ES2241678T3 (es) | 2005-11-01 |
DE60019964D1 (en) | 2005-06-09 |
WO2001044241A1 (en) | 2001-06-21 |
JP2003525872A (ja) | 2003-09-02 |
EP1240165A1 (en) | 2002-09-18 |
AU774381B2 (en) | 2004-06-24 |
TWI265930B (en) | 2006-11-11 |
CA2394544A1 (en) | 2001-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0300974A3 (en) | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases, pharmaceutical compositions containing them and their use | |
HUP0301032A3 (en) | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases, their use and pharmaceutical compositions containing them | |
HUP0004559A3 (en) | Aminothiazole inhibitors of cyclin dependent kinases, pharmaceutical compositions containing them and their use | |
HUP0301213A3 (en) | Aminothiazole inhibitors of cyclin dependent kinases, pharmaceutical compositions, their use and process for their preparation | |
HUP0303698A2 (hu) | Ciklin dependens kináz inhibitor N-[5-{[(5-alkil-2-oxazolil)-metil]-tio}-2-tiazolil]-karboxamid származékok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
HUP0203841A3 (en) | 5-membered heteroaromatic compounds and use thereof for preparation of pharmaceutical compositions, and pharmaceutical compositions containing them | |
PL352282A1 (en) | Derivatives of thiazoles and pharmaceutical compositions containing these derivatives | |
HUP0201214A3 (en) | Inhibitors of impdh enzyme, pharmaceutical compositions containing them and their use | |
HUP0301005A3 (en) | Pirrolotriazine inhibitors of kinases pharmaceutical compositions containing them and their use | |
HUP0202897A3 (en) | Diaminothiazoles and their use for inhibiting protein kinases and pharmaceutical compositions containing them | |
HUP0004512A3 (en) | 4-aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases | |
HUP0201261A3 (en) | Indole-type derivatives as inhibitors of p38 kinase and pharmaceutical compositions containing them | |
HUP0300318A3 (en) | Pyrazolobenzodiazepines as cdk2 inhibitors and pharmaceutical compositions containing them and their use | |
HUP0200155A3 (en) | Thioamide derivatives, pharmaceutical compositions containing them and their use | |
HUP0001170A3 (en) | Pharmaceutical compositions containing benzimidazole-2-carbamate derivatives as active ingredients for the treatment of viral infections and cancer | |
HUP0302412A3 (en) | Betha-carboline derivatives useful as inhibitors of phosphodiesterase and pharmaceutical compositions containing the same | |
HUP0303146A3 (en) | 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors and pharmaceutical compositions containing them | |
HUP0203376A3 (en) | 5-aryl-1h-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them and their use | |
HUP0201846A3 (en) | Amonobenzophenones as inhibitors of il-1betha and tnf-alpha and pharmaceutical compositions containing them | |
HUP0101899A3 (en) | Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes, pharmaceutical compositions comprising thereof and their use | |
PL352293A1 (en) | Derivatives of purine, method of making same and pharmaceutical compositions containing these derivatives | |
HUP0202520A3 (en) | Substituted benzylthiazolidine-2,4-dione derivatives and pharmaceutical compositions containing them | |
HUP0202401A2 (en) | Five-membered heterocyclic amidinec as prodrugs of thrombin inhibitors, pharmaceutical compositions comprising thereof and their use | |
AU2001277285A1 (en) | Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases | |
IL179865A0 (en) | Pharmaceutical composition comprising 5 - [[4-[3 - methyl- 4- oxo - 3,4 - dihydro - 2 - quinazolinyl]methoxy] phenyl-methyl]thiadiazolidine-2,4- dione in the form of a tablet a powder or a capsule and the process for its preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |